Subscribe
shutterstock_1807747930_ascannio
Ascannio / Shutterstock.com
16 September 2021AmericasMuireann Bolger

Intel backs Mylan's anti-Fintiv SCOTUS stance

Intel has backed Mylan's bid to convince the US Supreme Court to remove the controversial NHK-Fintiv rule, on the basis that it is  “unlawful”.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Mylan asks SCOTUS to end NHK-Fintiv rule
16 August 2021   Mylan Laboratories has urged the US Supreme Court to overturn the controversial NHK-Fintiv rule, claiming that it is “unlawful”.
Americas
Mylan, Edwards back NHK-Fintiv challenge
31 August 2021   Mylan Pharmaceutical and Edwards Lifesciences have joined a petition urging the US Supreme Court to order the US Court of Appeals for the Federal Circuit to reconsider inter partes review petitions that have been denied due to the NHK-Fintiv rule.
Generics
Lawmakers urge USPTO to curb IPR denials under Fintiv
21 September 2021   Several US lawmakers have called upon the US Patent and Trademark Office to curb the increase in inter partes review denials to combat the “soaring cost” of prescription drugs.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Americas
Mylan asks SCOTUS to end NHK-Fintiv rule
16 August 2021   Mylan Laboratories has urged the US Supreme Court to overturn the controversial NHK-Fintiv rule, claiming that it is “unlawful”.
Americas
Mylan, Edwards back NHK-Fintiv challenge
31 August 2021   Mylan Pharmaceutical and Edwards Lifesciences have joined a petition urging the US Supreme Court to order the US Court of Appeals for the Federal Circuit to reconsider inter partes review petitions that have been denied due to the NHK-Fintiv rule.
Generics
Lawmakers urge USPTO to curb IPR denials under Fintiv
21 September 2021   Several US lawmakers have called upon the US Patent and Trademark Office to curb the increase in inter partes review denials to combat the “soaring cost” of prescription drugs.

More on this story

Americas
Mylan asks SCOTUS to end NHK-Fintiv rule
16 August 2021   Mylan Laboratories has urged the US Supreme Court to overturn the controversial NHK-Fintiv rule, claiming that it is “unlawful”.
Americas
Mylan, Edwards back NHK-Fintiv challenge
31 August 2021   Mylan Pharmaceutical and Edwards Lifesciences have joined a petition urging the US Supreme Court to order the US Court of Appeals for the Federal Circuit to reconsider inter partes review petitions that have been denied due to the NHK-Fintiv rule.
Generics
Lawmakers urge USPTO to curb IPR denials under Fintiv
21 September 2021   Several US lawmakers have called upon the US Patent and Trademark Office to curb the increase in inter partes review denials to combat the “soaring cost” of prescription drugs.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool
USPTO clarifies AI's role in patent eligibility